A component of earthworm fibrinolytic enzyme having higher thrombolytic activity than total components in vivo.
- Author:
Xiao-yu ZHAO
1
;
Ze-ming LIU
;
Tian-yu JING
;
Jin-xia WU
;
Zhuan-you ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Amino Acid Sequence; Animals; Bleeding Time; Dogs; Electrophoresis, Polyacrylamide Gel; Female; Fibrinogen; metabolism; Fibrinolytic Agents; chemistry; isolation & purification; pharmacology; toxicity; Lethal Dose 50; Male; Mice; Molecular Sequence Data; Molecular Weight; Oligochaeta; chemistry; enzymology; Rats; Rats, Wistar; Sequence Analysis, Protein; Spectrophotometry, Infrared; Venous Thrombosis; blood; drug therapy
- From: Acta Pharmaceutica Sinica 2006;41(11):1068-1073
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo select higher thrombolytic and lower toxic single component of earthworm fibrinolytic enzymes (EFE).
METHODSEFE containing total components were obtained by affinity chromatography from Eisenia fetida. Using ion-exchange chromatography to separate three main components EfP-0-2, EfP-I-1 and EfP-I-2 from EFE, their thrombolytic activity and toxicity were compared with EFE.
RESULTSAmong these components, EfP-I-1 had higher thrombolytic activity in vitro. When 4.5 mg x kg(-1) of these components were injected, the contents of fibrinogen in rat serum were not affected, but only EfP-I-1 exhibited distinct thrombolytic activity. When 6.0 mg x kg(-1) of them were injected intravenously, the bleeding time was not evidently delayed only by EfP-I-1. The acute toxicity test showed that the LD50 of EfP-I-1 was higher than EFE by 2. 17 times.
CONCLUSIONBecause of distinct thrombolytic activity, lower toxicity in vivo, higher content in EFE and easy to purify, EfP-I-1 was adapted to be developed as a single component medicine for treating thrombus.
